Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial

Jacob Elkins(Biogen (United States)), Mitchell S.V. Elkind, Lahar Mehta(Biogen (United States)), Weihua Tang(Zhejiang Sci-Tech University), Kyra J. Becker(University of Washington), Maarten G. Lansberg(Stanford University), Joan Montaner(Universitat Autònoma de Barcelona), Ih Chang(Biogen (United States)), Kumar Kandadi Muralidharan(Biogen (United States)), Sarah Gheuens(Biogen (United States)), Aneesh B. Singhal(Massachusetts General Hospital), Roland Veltkamp(Heidelberg University), S. Claiborne Johnston(University of Nottingham)
The Lancet Neurology
February 15, 2017
10.1016/s1474-4422(16)30357-x
Cited by 213

Related Papers

Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
|Stroke|2019|7.2k
Heart Disease and Stroke Statistics—2021 Update
|Circulation|2021|5.7k
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
|Stroke|2018|5.5k